#BristolMyers
Up and Down the Ladder: Job Changes.. the latest comings and goings.. recognize anyone? statnews.com/pharmalot/20... #pharma #biotech #jobs #NovoNordisk #BristolMyers #AstraZeneca
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
statnews.com
January 16, 2026 at 7:33 PM
Pharmalot.. Pharmalittle.. Good Morning: We’re reading about a ‘breached’ FDA firewall, an AbbVie pricing deal with Trump, and more news.. statnews.com/pharmalot/20... #pharma #Trump #HIV #abortion #340B #FDA #Nvidia #Lilly #BristolMyers #Gilead #AbbVie #CVS
Pharmalittle: We're reading about a 'breached' FDA firewall, an AbbVie pricing deal with Trump, and more
A veteran FDA regulator who left last month said the firewall between agency political appointees and drug reviewers “has been breached"
statnews.com
January 13, 2026 at 2:39 PM
BUFFERIN
√ acts twice as fast as aspirin …
√ won’t upset your stomach ….’
Bufferin - a product of Bristol-Myers. January 1957.
#illustration #illustrationart #graphicdesign #Bufferin #BristolMyers
January 8, 2026 at 1:48 PM
Up and Down the Ladder: Job Changes.. the latest comings & goings.. recognize anyone? statnews.com/pharmalot/20...
#pharma #biotech #jobs #BristolMyers #AstraZeneca
Up and down the ladder: The latest comings and goings
With new personnel moves at Ovid Therapeutics, Bristol Myers Squibb, AstraZeneca, and more, here are the latest comings and goings in the pharma industry.
statnews.com
December 12, 2025 at 5:18 PM
Pharmalot.. Pharmalittle.. Good Morning: We’re reading about a Merck acquisition, Novo facing shareholder backlash, and more news.. statnews.com/pharmalot/20... #pharma #flu #opioids #Merck #NovoNordisk #JNJ #BristolMyers #Lundbeck #Alkermes #Cidara
Pharmalittle: We're reading about a Merck acquisition, Novo facing shareholder backlash, and more
Merck agreed to buy Cidara Therapeutics, the maker of an experimental flu therapy, in a $9.2 billion deal
statnews.com
November 14, 2025 at 3:08 PM
Pharmalot.. Pharmalittle.. Good Morning: We’re reading about dueling data from Lilly and Novo, a Roche deal & much more news.. statnews.com/pharmalot/20... #pharma #weight #obesity #layoffs #Ireland #GLP1 #lungcancer #Merck #Lilly #NovoNordisk #Roche #AstraZeneca #BristolMyers
Pharmalittle: We're reading about dueling data from Lilly and Novo, a Roche deal, and much more
Novo Nordisk's diabetes blockbuster Ozempic beat Eli Lilly’s older drug Trulicity in a real-world study of certain U.S. patients
statnews.com
September 18, 2025 at 1:23 PM
Up and Down the Ladder: Job Changes .. the latest comings & goings.. recognize anyone? statnews.com/pharmalot/20... #pharma #biotech #jobs #Gilead #EliLilly #BristolMyers #Novartis
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
statnews.com
August 22, 2025 at 6:41 PM
pharmalot
@pharmalot
·
1s
Up and Down the Ladder : Job Changes.. the latest comings & goings.. recognize anyone? statnews.com/pharmalot/20... #pharma #biotech #jobs #Merck #GSK #Novartis #NovoNordisk #BristolMyers
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
statnews.com
August 1, 2025 at 5:46 PM
Bristol Myers posts better-than-expected second quarter results on strength of top sellers
By Michael Erman (Reuters) -Bristol Myers Squibb posted much better-than-expected second-quarter results on Wednesday on strong sales of its most established and best-selling brands, blood thinner Eliquis and cancer treatments Opdivo and Revlimid. Shares of the drugmaker rose more than 2% to $47 in premarket trading. Revenue in the quarter, which analysts had expected to fall due to the loss of patent protection on some of its products, including Revlimid, rose 1% to $12.3 billion. Analysts, on average, were looking for revenue of $11.4 billion, according to LSEG data. The U.S. drugmaker said it earned $2.9 billion, or $1.46 per share, down from $4.2 billion, or $2.07, a year earlier. Analysts had expected earnings of $1.07 a share. "The majority of our brands outperformed consensus in the quarter," Chief Financial Officer David Elkins said in an interview. "We just have really solid commercial execution." Sales of Eliquis, which Bristol Myers (NYSE:BMY) shares with Pfizer (NYSE:PFE), rose 8% to $3.7 billion in the quarter, while cancer immunotherapy Opdivo brought in $2.6 billion, up 7% from a year ago. Analysts, on average, had forecast sales of $3.3 billion and $2.3 billion for those drugs, respectively. Revlimid sales fell 38% to $838 million, but still topped analyst estimates by about $300 million. Bristol has been contending with a steep revenue decline from Revlimid, which raked in nearly $13 billion in 2021 but $5.8 billion last year due to generic rivals. Some of its other cancer drugs such as Pomalyst, Sprycel and Abraxane are contending with the same issue. Still, Revlimid has held up better than initially feared, and the company now expects 2025 sales of around $3 billion, Chief Commercialization Officer Adam Lenkowsky said. The company had previously said it expected 2025 Revlimid sales to be near $2.5 billion. It now expects full-year earnings, including a charge from a development deal with Germany’s BioNTech (NASDAQ:BNTX), to be $6.35 to $6.65 a share. Analysts are estimating 2025 earnings of around $6.24 per share.
www.investing.com
July 31, 2025 at 11:50 AM
Pharmalot.. Pharmalittle.. Good Morning: We’re reading about a Bristol-Pfizer direct-to-consumer sales plan, Sarepta layoffs & lots more news.. statnews.com/pharmalot/20... #pharma #medicines #obesity #diabetes #syphilis #wegovy #zepbound #Trump #dementia #layoffs #Pfizer #Sarepta #BristolMyers
Pharmalittle: We're reading about a Bristol-Pfizer direct-to-consumer sales plan, Sarepta layoffs, and more
Report found business relationships between telehealth and pharma companies may indirectly lead patients toward certain branded drugs
statnews.com
July 17, 2025 at 1:28 PM
Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients
(Reuters) -Bristol Myers and Pfizer (NYSE:PFE) said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to cash-paying U.S. patients at a discount to its listed price as drugmakers are under pressure from the Trump administration to lower prices. The initiative - which would bypass traditional pharmacy benefit managers and insurers - offers a roughly 43% discount from the list price, cutting the treatment’s monthly cost from around $606 to $346. But it would still cost over 9 times the average out-of-pocket cost paid by commercially insured patients. It is also significantly higher than the $231 per month Medicare price that former President Joe Biden’s administration negotiated under the Inflation Reduction Act, which is set to take effect next year, and the price of the drug abroad. "This discount is not as meaningful as that delivered through the IRA negotiations - those discounts have been ridiculed by Trump as not meaningful, so there’s potential for skepticism from the administration on this offer," Bernstein analyst Courtney Breen said in a note. While more than 90% of Eliquis prescriptions in the U.S. are currently covered through insurance, the drugmakers say the initiative aims to expand access, reduce out-of-pocket burden, and provide transparent pricing and direct support. Meanwhile, the Trump administration has ramped up efforts to tackle high U.S. prescription drug prices through a "most-favored-nation" (MFN) policy, aiming to align domestic prices with the lowest levels paid by comparable high-income countries. According to a 2024 report from the Senate’s Health, Education, Labor and Pensions committee, the cost of Eliquis was around $55 a month in France and $65 a month in the UK and Germany. Since its launch, Eliquis has been prescribed to over 15 million Americans and in 2024 it generated about $11.4 billion in global revenue.
www.investing.com
July 17, 2025 at 1:28 PM
Up and Down the Ladder: Job Changes.. the latest comings & goings.. recognize anyone? statnews.com/pharmalot/20... #pharma #biotech #jobs #Pfizer #AstraZeneca #Sanofi #BristolMyers
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
statnews.com
June 13, 2025 at 4:02 PM
www.newsmason.com
June 4, 2025 at 3:45 AM
www.newsmason.com
June 3, 2025 at 5:12 AM
That’s a great spot for them. Whereas a lot of the other HQ campuses(Novartis, BristolMyers) nearby aren’t walkable to local restaurants, there are a lot of good places to eat within 100yds of this. Has the potential to really boost downtown Morristown.
May 23, 2025 at 8:31 PM
#THISWEEK in 1950
‘Keep your *Whole* Mouth *Wholesome*!’
Ipana Toothpaste
*Collier’s* May 13, 1950
#Ipana #ToothPaste #BristolMyers #womensfashion #Mensfashion #GraphicDesign #1950s
May 17, 2025 at 4:29 PM
Up and Down the Ladder: Job Changes.. the latest comings & goings.. recognize anyone? statnews.com/pharmalot/20... #pharma #biotech #jobs #CVS #BristolMyers
Up and down the ladder: The latest comings and goings
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with
statnews.com
February 21, 2025 at 6:50 PM
Wyden received campaign contributions from Amgen,Pfizer,Johnson&Johnson,Merck,BristolMyers,Squibb,AbbVie,AstraZeneca,Sanofi over the years. For the 2019-24 cycle, he received +$700k from the pharmaceutical industry via his campaign and PACs
January 31, 2025 at 6:29 PM
BUFFERIN
√ acts twice as fast as aspirin …
√ won’t upset your stomach ….’
Bufferin - a product of Bristol-Myers. January 1957.
#illustration #illustrationart #graphicdesign #Bufferin #BristolMyers
January 8, 2025 at 3:00 PM
Prices for 5 drugs were hiked without proof of new benefits, costing the U.S. $815M in 2023, report finds.. statnews.com/pharmalot/20... #pharma #biotech #medicines #HIV #cancer #Gilead #BristolMyers #J&J #Pfizer #Novartis #AstraZeneca
Prices for 5 drugs were hiked without proof of new benefits, costing the U.S. $815M in 2023, report finds
Report: Prices for 5 drugs were hiked without proof of new benefits, costing the U.S. $815 million in 2023.
statnews.com
December 12, 2024 at 1:06 PM
Sal Hepatica. Found in many homes in the mid-20th century. Being high in salt content, it would cause more problems then it would solve. Was taken off the shelves as more effective laxatives were created.
#SalHepatic #BristolMyers #medicines #laxatives #gout #vintage #saline
March 7, 2024 at 1:26 PM
As the market starts to cool down, Cramer says don't be afraid to stay bullish
#jimcramer #apple #merck #bristolmyers #restaurant #brinker

➡️ Now on https://biztoc.comhttps://www.cnbc.com/2023/06/03/as-the-market-starts-to-cool-down-cramer-says-stay-bullish-.html
June 3, 2023 at 7:48 PM